{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:16:42Z","timestamp":1703204202942},"reference-count":18,"publisher":"ALUNA","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>The aim: To study the risk factors of cardiovascular diseases in patients with coronary heart disease with stable angina pectoris II functional class in combi\u00acnation with NAFLD. \nMaterials and methods: The study included 245 patients with a diagnosis of CHD, stable angina pectoris II functional class (FC), who were being treated at the Communal Nonprofit Enterprise \u00abCentral City Clinical Hospital\u00bb of Uzhhorod City Council. We singled out 2 groups of patients: group 1 (n=145) \u2013 patients with CHD with stable angina pectoris II FC in combination with NAFLD and group 2 (n=100) \u2013 patients with CHD with stable angina pectoris II FC. \nResults: Analysis of the frequency of occurrence of CVD risk factors in patients with CHD showed that among patients of group 1 there are 50% more people with abdominal obesity, excess body and dyslipidemia. The reliability between the groups in the occurrence of hypertension and type 2 diabetes was not revealed. The obtained results confirm the data that the prevalence of NAFLD increases with increasing body weight and a high degree of obesity increases the risk of its development. \nConclusions: The most frequent risk factors for CVD in patients with coronary artery disease in combination with NAFLD are hypertension, obesity, and dyslipidemia.<\/jats:p>","DOI":"10.36740\/wlek202311106","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:31:38Z","timestamp":1703165498000},"page":"2378-2382","source":"Crossref","is-referenced-by-count":0,"title":["ASSESSMENT OF CARDIOVASCULAR DISEASE RISK FACTORS IN PATIENTS WITH CORONARY HEART DISEASE COMBINED WITH NONALCOHOLIC FATTY LIVER DISEASE"],"prefix":"10.36740","volume":"76","author":[{"given":"Yaroslav Y.","family":"Ihnatko","sequence":"first","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Derbak","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Lukach","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kseniya I.","family":"Chubirko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleksandr O.","family":"Boldizar","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olesia I.","family":"Ihnatko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2023]]},"reference":[{"key":"ref0","unstructured":"1. Oksak HA. Medyko-sotsialne obgruntuvannia optymizovanoi modeli nadannia tretynnoi medychnoi dopomohy khvorym z hostrym infarktom miokarda. [Medical and social justification of the optimized model provision of tertiary medical care to patients with acute heart attack myocardium.] [dissertation] Poltava: Ukrainska medychna stomatolohichna akademiia, Ministerstvo Okhorony Zdorovia Ukrainy. 2021, \u0440.281. http:\/\/repository.pdmu.edu.ua\/bitstream\/123456789\/15586\/5\/Oksak_dys.pdf [date access 03.05.2023] (in Ukrainian)."},{"key":"ref1","unstructured":"2. Sertsevo-sudynni zakhvoryuvannya \u2014 holovna prychyna smerti ukrayintsiv. Vysnovky z doslidzhennya hlobal'noho tyaharya khvorob u 2019 rotsi. https:\/\/phc.org.ua\/news\/sercevo-sudinni-zakhvoryuvannya-golovna-prichina-smerti-ukrainciv-visnovki-z-doslidzhennya. Tsentr hromads'koho zdorov\u2019ya MOZ Ukrayiny. [date access 03.05.2023] (in Ukrainian)."},{"key":"ref2","unstructured":"3. Kapshytar NI. Udoskonalennia diahnostyky, prohnozuvannia ta likuvannia Q-infarktu miokarda, uskladnenoho hostroiu sertsevoiu nedostatnistiu na tli hiperhlikemii.[Improvement of diagnosis, prognosis and treatment Q-myocardial infarction complicated by acute heart failure dissertation against the background of hyperglycemia.] [dysertatsiia]. Zaporizhzhia: Zaporizkyi derzhavnyi medychnyi universytet, Ministerstvo Okhorony Zdorovia Ukrainy. 2020, \u0440.240. http:\/\/dspace.zsmu.edu.ua\/bitstream\/123456789\/15779\/1\/09062020_dis_ kapshytar.pdf [date access 03.05.2023] (In Ukrainian)."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Andonieva NM, Berezin OIe, Berezin OO et al. Arterialna hipertenziia ta komorbidnist : monohrafiia. [Arterial hypertension and comorbidity: monograph \/ by ed. O. M. Bilovola.] \u2013 Kharkiv : KhNMU. 2019, \u0440.176. https:\/\/repo.knmu.edu.ua\/bitstream\/123456789\/28070\/1\/%D0%91 %D1%96%D0%BB%D0%BE%D0%B2%D0%BE%D0%BB%2_%D0%93%D0%A5%20%D1%82%D0%B0%20%D0%BA%D0%BE %D0%BC%D0%BE%D1%80%D0%B1%D1%96%D0%B4%D0%BD%D1%96%D1%81%D1%82%D1%8C_%D0%BC%D0%BE% D0%BD%D0%BE%D0%B3%D1%80%D0%B0%D1%84%D1%96%D1%8F.pdf [date access 03.05.2023] (in Ukrainian).","DOI":"10.33941\/age-info.com24(5)2018005"},{"key":"ref4","unstructured":"5. Labinska OIe. Vplyv reperfuziinoi terapii na yakist zhyttia patsiientiv iz hostrym infarktom miokarda za naiavnosti ozhyrinnia.[ The effect of reperfusion therapy on the quality of life of patients with acute myocardial infarction in the presence of obesity.] Praktykuiuchyi likar. 2022;11(2\u20133):29\u201334. https:\/\/plr.com.ua\/index.php\/journal\/article\/download\/712\/588 [date access 03.05.2023] (in Ukrainian)."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Yefimenko TI, Mykytiuk MR. Nealkoholna zhyrova khvoroba pechinky: chas dlia zmin. [ Non-alcoholic fatty liver disease: time for changes International journal of endocrinology.] Mizhnarodnyi endokrynolohichnyi zhurnal. 2021;17(4):334-\u00ac345. doi: 10.22141\/2224- 0721.17.4.2021.237350. (In Ukrainian).","DOI":"10.22141\/2224-0721.17.4.2021.237350"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP reports. 2020\u037e2(6):100-192. doi:10.1016\/j.jhepr.2020.100192.","DOI":"10.1016\/j.jhepr.2020.100192"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Chung GE, Cho EJ, Yoo J\u00acJ et al. Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke. Diabetes, Obes Metab. 2022\u037e24(3):465\u201372. doi:10.1111\/dom.14597.","DOI":"10.1111\/dom.14597"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Bentsa TM. Nealkoholna zhyrova khvoroba pechinky ta sertsevo-sudynni zakhvoriuvannia: osoblyvosti komorbidnoho perebihu. [Nonalcoholic fatty liver disease and cardiovascular diseases: features of the comorbid course.] Liky Ukrainy. 2020;237(1):44-47. http:\/\/ lu-journal.com.ua\/article\/download\/214176\/214285\/0 [date access 03.05.2023] (in Ukrainian).","DOI":"10.37987\/1997-9894.2020.1(237).214176"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Bentsa TM. Terapevtychni aspekty nealkoholnoi zhyrovoi khvoroby pechinky.[ Therapeutic aspects of non-alcoholic fatty disease liver Medicines of Ukraine.] Liky Ukrainy. 2022;(8(264)):18\u201321. http:\/\/lujournal.com.ua\/article\/view\/271835\/ [date access 03.05.2023] (In Ukrainian).","DOI":"10.37987\/1997-9894.2022.8(264).271835"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Stepanov YuM, Filippova OIu. Evoliutsiia uiavlen pro nealkoholnu zhyrovu khvorobu pechinky: vid ryzyku do katastrofy. [The evolution of ideas about non-alcoholic fatty liver disease: from risk to disaster] Zaporozhskyi medytsynskyi zhurnal. Zaporozhye Med J. 2020;2:267\u201374. doi: 10.14739\/2310-1210.2020.2.200637. (In Ukrainian).","DOI":"10.14739\/2310-1210.2020.2.200637"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Kushnir IE. Nealkoholna zhyrova khvoroba pechinky: suchasni metody diahnostyky ta stratehii likuvannia. Suchasna hastroenterolohiia. [Non-alcoholic fatty liver disease: modern methods diagnostics and treatment strategies]. Suchasna hastroenterolohiya. 2020;3(113):51\u2013 61. doi: 10.30978\/MG-2020-3-51. (in Ukrainian).","DOI":"10.30978\/mg-2020-3-51"},{"key":"ref12","unstructured":"13. Nakaz MOZ Ukrainy \u2116 826 vid 06.11.2014 r. Pro zatverdzhennia unifikovanoho klinichnoho protokolu pervynnoi, vtorynnoi (spetsializovanoi) medychnoi dopomohy \u00abNealkoholnyi steatohepatyt\u00bb. Kyiv. [Order of the Ministry of Health of Ukraine No. 826 of 06.11.2014 on approval unified clinical protocol of primary, secondary (specialized) medical care \u201cNon-alcoholic steatohepatitis\u201d.] 2014. https:\/\/ukrgastro.com.ua\/edu-snc\/protocols\/unifikovaniy-klinichniy-protokol-pervinnoyi-vtorinnoyi-specializovanoyi-medichnoyi-dopomogi-nealkogolniy-steatogepatit [date access 03.05.2023] (In Ukrainian)."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Poda OA. Suchasni kryterii veryfikatsii ta osnovni pryntsypy vedennia nealkoholnoi zhyrovoi khvoroby pechinky. [Modern verification criteria and basic management principles non-alcoholic fatty liver disease.] Problemy ekolohiyi ta medytsyny. 2021;25(1\u2013 2):50\u20136. doi: 10.31718\/mep.2021.25.1-2.13 (In Ukrainian).","DOI":"10.31718\/mep.2021.25.1-2.13"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Brunner KT, Henneberg CJ, Wilechansky RM, Long MT. Nonalcoholic fatty liver disease and obesity treatment. Curr Obes Rep. 2019;8(3):220\u2013 8. doi: 10.1007\/s13679-019-00345-1.","DOI":"10.1007\/s13679-019-00345-1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397. doi: 10.1016\/j.metabol.2018.11.014.","DOI":"10.1016\/j.metabol.2018.11.014"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Hernandez-Baixauli J, Quesada-V\u00e1zquez S, Marin\u00e9-Casad\u00f3 R et al. Detection of early disease risk factors associated with metabolic syndrome: a new era with the NMR metabolomics assessment. Nutrients. 2020;12:806. doi:10.3390\/nu12030806.","DOI":"10.3390\/nu12030806"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Hassen G, Singh A, Belete G et al. Nonalcoholic fatty liver disease: An emerging modern-day risk factor for cardiovascular disease. Cureus. 2022;14(5). doi: 10.7759\/cureus.25495.","DOI":"10.7759\/cureus.25495"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T14:28:46Z","timestamp":1703168926000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2023\/WiadLek2023i11.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023]]},"published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202311106","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}